News center More...

18 2025-09
Gluetacs Therapeutics Submits Pre-IND Application to the CDE for GT818, a First-in-Class RSK Bifunctional Degrader, for the Treatment of Advanced Malignant Tumors
04 2025-09
Gluetacs Therapeutics was successfully approved for the “2025 Lingang Special Area Patent Navigation Project.”
27 2025-05
Gluetacs was honored with the “Future Star Alumni Enterprise Award” at the 6th University of Chinese Academy of Sciences (UCAS) Alumni Innovation Forum.
15 2025-03
Gluetacs Therapeutics and Fudan University’s Sun Tao/Jiang Chen team develop a PROTAC-loaded nanocapsule targeting BRD4 degradation to break through the radiochemotherapy resistance bottleneck in glioblastoma
15 2025-03
Gluetacs Therapeutics and Fudan University’s Sun Tao/Jiang Chen team develop a PROTAC-loaded nanocapsule targeting BRD4 degradation to break through the radiochemotherapy resistance bottleneck in glioblastoma
04 2025-01
Conference Express |Gluetacs Therapeutics Will Attend the 2025 J.P. Morgan & BIOTECH SHOWCASE Annual International Conference
28 2024-12
Good news! Gluetacs Therapeutics won Top 100 of the Shanghai High-Value Patent Operation Competition and awarded the title of Director Unit of the National Biopharmaceutical Enterprise Platform